RxDoctor Payments Data

Ramesh Shivani, MD

Psychiatry · Hillsboro, OHNPI 1477545390

Payments from drug & device makers

$30,739in general payments, 2019–2025

Across 166 payments — averaging $185.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$28K
  • Otsuka America Pharmaceutical, Inc.$580
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$332
  • Teva Pharmaceuticals USA, Inc.$307
  • Axsome Therapeutics, Inc.$290
  • Lundbeck LLC$192
  • plus $1K from 12 others

What the payments were for

  • Speaking & faculty fees$26,72587%
  • Food & beverage$3,96413%
  • Education$500%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,739 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in Ohio.

See all psychiatry providers in Ohio

Medicare billing

Part B allowed, 2024
$11,474
Medicare patients
51
Services billed
146

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole81$123,156
VraylarCariprazine Hcl75$111,920
CaplytaLumateperone Tosylate46$72,076
Aripiprazole248$22,624
Desvenlafaxine Succinate ErDesvenlafaxine Succinate81$11,390
TrintellixVortioxetine Hydrobromide12$7,317
Duloxetine Hcl383$6,194
Quetiapine Fumarate316$5,724
Atomoxetine Hcl54$5,235
Buspirone Hcl524$4,848
Hydroxyzine Hcl270$3,624
Trazodone Hcl520$3,350
Venlafaxine Hcl ErVenlafaxine Hcl139$3,092
Vilazodone Hcl39$2,784
Ziprasidone Hcl78$2,747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$580$123,15681 claims
AbbVieVraylar$27,827$111,92075 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$332$72,07646 claims
Lilly USA, LLCOlanzapine$118$1,712100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in Ohio.

Other psychiatry in Hillsboro

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →